Multigram-Scale Access to 2-Oxaadamantan-1-amine and 2-Oxaadamantan-1-ol via Optimized Synthesis of Bicyclo[3.3.1]nonane-3,7-dione
Journal of Organic and Pharmaceutical Chemistry · 04.05.2026 · 24 (1) · 46-52
DOI: 10.24959/ophcj.26.357366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Organic and Pharmaceutical Chemistry, online erschienen am 04.05.2026. Verfasst von Ioann O. Popov und 1 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Practical, tens-of-grams-scale access to 2-oxaadamantan-1-amine and 2-oxaadamantan-1-ol – two overlooked heteroadamantane building blocks of interest for medicinal chemistry – has been achieved through optimization and scale-up of existing literature protocols. The key precursor, bicyclo[3.3.1]nonane-3,7-dione, and both target compounds are obtained in good overall yields using straightforward procedures and standard reagents. Notably, 2-oxaadamantan-1-amine is an exceptionally stable N,O-acetal, in stark contrast to the high hydrolytic lability usually seen in this compound class.
Zitieren
APA
Popov, I. O., & Volochnyuk, D. M. (2026). Multigram-Scale Access to 2-Oxaadamantan-1-amine and 2-Oxaadamantan-1-ol via Optimized Synthesis of Bicyclo[3.3.1]nonane-3,7-dione. Journal of Organic and Pharmaceutical Chemistry, 24(1), 46-52. https://doi.org/10.24959/ophcj.26.357366
Vancouver
Popov IO, Volochnyuk DM. Multigram-Scale Access to 2-Oxaadamantan-1-amine and 2-Oxaadamantan-1-ol via Optimized Synthesis of Bicyclo[3.3.1]nonane-3,7-dione. Journal of Organic and Pharmaceutical Chemistry. 2026;24(1):46-52. doi:10.24959/ophcj.26.357366
BibTeX
@article{Popov2026,
author = {Popov, Ioann O. and Volochnyuk, Dmytro M.},
title = {Multigram-Scale Access to 2-Oxaadamantan-1-amine and 2-Oxaadamantan-1-ol via Optimized Synthesis of Bicyclo[3.3.1]nonane-3,7-dione},
journal = {Journal of Organic and Pharmaceutical Chemistry},
year = {2026},
volume = {24},
number = {1},
pages = {46--52},
doi = {10.24959/ophcj.26.357366}
}
EUVIMED